Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

DILANTIN

PHENYTOIN SODIUM

Standard Dose
30MG EXTENDED
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview DILANTIN is listed in Drugs@FDA under application 084349 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PHENYTOIN SODIUM Form and strength CAPSULE;ORAL - 30MG EXTENDED Sponsor VIATRIS Submission history Latest submission status date: 2022-09-07 00:00:00.

Structured Monograph

Clinical summary

Approval overview DILANTIN is listed in Drugs@FDA under application 084349 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PHENYTOIN SODIUM Form and strength CAPSULE;ORAL - 30MG EXTENDED Sponsor VIATRIS Submission history Latest submission status date: 2022-09-07 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.